GlobeNewswire

Immunicum AB (publ) arrangerar virtuellt investerarevent den 9 december

Dela

Pressmeddelande

1 december 2020

Immunicum AB (publ) arrangerar virtuellt investerarevent den 9 december

Immunicum AB (publ) (IMMU.ST) meddelar idag att bolaget kommer att arrangera ett virtuellt investerarevent onsdagen den 9 december klockan 15:00 CET.

Under eventet kommer Immunicum att presentera en översikt av den föreslagna transaktionen med DCprime, inklusive en frågestund.

Program och länk till det virtuella eventet kommer att finnas på www.immunicum.com innan eventet. Frågor kan skickas in på förhand och under eventet till ir@immunicum.com.

FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA:

Sven Rohmann, VD
Telefon: 08 732 8400
E-post: info@immunicum.com

Investor Relations

Jonas Rodny och Carolin Wiken
Paues Åberg Communications
Telefon: 076 190 90 51
E-post: ir@immunicum.com

Media Relations

Joanne Tudorica och Sophia Hergenhan, Ph.D.
Trophic Communications
Telefon: +49 171 351 2733
E-post: ir@immunicum.com

Om Immunicum AB (publ)

Immunicum etablerar ett unikt angreppssätt inom immunonkologi genom utveckling av lagringsbara allogena cellbaserade terapier. Vårt mål är att bekämpa cancer genom att aktivera och stärka patientens eget immunförsvar, och därmed förbättra överlevnad och livskvalitet.  Bolagets huvudprodukt ilixadencel, som består av pro-inflammatoriska allogena dendritiska celler, har potentialen att bli en grundkomponent i moderna kombinationsbehandlingar i flertalet solida tumörindikationer. Immunicum har utvärderat ilixadencel i flera olika kliniska studier, inklusive den nyligen avslutade explorativa fas II-studien MERECA inom njurcancer och bolaget går för närvarande mot klinisk utveckling i sen fas.  Immunicum är grundat och baserat i Sverige och är noterat på Nasdaq Stockholm. www.immunicum.com

Bilaga


Om

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Följ GlobeNewswire

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire

Cargotec’s financial statements review 2020 to be published on Thursday, 4 February 202121.1.2021 08:30:00 CETPress release

CARGOTEC CORPORATION, PRESS RELEASE, 21 JANUARY 2021 AT 9:30 AM (EET) Cargotec’s financial statements review 2020 to be published on Thursday, 4 February 2021 Cargotec Corporation will publish its financial statements review 2020 on Thursday, 4 February 2021 at approximately 1:30 p.m. EET. The report will be available at www.cargotec.com after publication. A live international telephone conference for analysts, investors and media will be arranged on the publishing day at 3:00 p.m. EET. The event will be held in English. The report will be presented by CEO Mika Vehviläinen and Executive Vice President, CFO Mikko Puolakka. The presentation material will be available at www.cargotec.com by the latest 2:30 p.m. EET. The telephone conference, during which questions may be presented, can be accessed by registering here. The registration opens 15 minutes prior to the event. The event conferencing system will call the participant on the phone number provided and place the participant into the

NICE recommends Jyseleca® ▼(filgotinib) on NHS in landmark decision for rheumatoid arthritis21.1.2021 08:08:24 CETPress release

NOT FOR DISTRIBUTION IN THE UNITED KINGDOM NICE guidance, for the first time in the UK, supports access to an advanced therapy for people with moderate as well as severe rheumatoid arthritis (RA) - aiming to avoid irreversible damage as early as possible1More than 400,000 people across the UK live with RA2 and around 70% have moderate or severe disease3 Mechelen, Belgium, 21 January 2021, 08:05 CET – Galapagos NV (Euronext & Nasdaq: GLPG) today welcomed the news that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination (FAD) recommending the use of the daily oral pill, JYSELECA®▼ (filgotinib) on the National Health Service (NHS) in England for the treatment of eligible adult patients with moderate to severe active rheumatoid arthritis (RA).1 It is the first time in the UK that an advanced therapy has been recommended in people with moderate RA, offering thousands more the potential to achieve remission earlier - potentially slowing the

Conference call to present Kinnevik’s fourth quarter and full-year results 202021.1.2021 08:00:00 CETPress release

Kinnevik AB (publ) ("Kinnevik") will publish financial results for the fourth quarter and full-year 2020 on Thursday 4 February 2021 at around 08.00 CET. A conference call will be held on the same day at 10.00 CET to present the results. The presentation will be held in English and also be made available via audiocast on Kinnevik’s website, www.kinnevik.com. Link to the audiocast: https://edge.media-server.com/mmc/p/a97or8rx Those who wish to participate in the conference call are welcome to dial-in on the below numbers. To ensure that you are connected to the conference call, please dial in and register your attendance a few minutes before the conference call begins. Dial-in numbers: UK: +44 3333 000 804 SE: +46 8 566 426 51 US: +1 631 913 1422 Confirmation code: 69100644# For further information, visit www.kinnevik.com or contact: Torun Litzén, Director Investor Relations Phone +46 (0)70 762 00 50 Email press@kinnevik.com Kinnevik is an industry focused investment company with an ent

Telefonkonferens och presentation av Kinneviks resultat för fjärde kvartalet och helåret 202021.1.2021 08:00:00 CETPressemelding

Kinnevik AB (publ) ("Kinnevik") kommer att offentliggöra resultatet för det fjärde kvartalet och helåret 2020 torsdagen den 4 februari 2021 cirka kl. 08.00 CET. En telefonkonferens kommer att hållas samma dag kl. 10.00 CET för att presentera resultatet. Presentationen kommer att hållas på engelska och även finnas tillgänglig som audiocast på Kinneviks webbplats, www.kinnevik.com. Länk till audiocast: https://edge.media-server.com/mmc/p/a97or8rx De som vill delta i telefonkonferensen i samband med presentationen är välkomna att ringa in på nedanstående nummer. För att vara säker på att uppkopplingen till konferenssamtalet fungerar, ring in några minuter innan konferensen börjar för att registrera er. Telefonnummer: UK: +44 3333 000 804 SE: +46 8 566 426 51 US: +1 631 913 1422 Kod: 69100644# För ytterligare information, besök www.kinnevik.com eller kontakta: Torun Litzén, Informations- och IR-chef Telefon +46 (0)70 762 00 50 Email press@kinnevik.com Kinnevik är ett sektorfokuserat invest

Huhtamaki invests in new state-of-the-art manufacturing unit in Malaysia21.1.2021 08:00:00 CETPress release

HUHTAMÄKI OYJ PRESS RELEASE 21.1.2021 AT 09:00 Huhtamaki invests in new state-of-the-art manufacturing unit in Malaysia Huhtamaki, a key global provider of sustainable packaging solutions for consumers around the world, is investing in a new manufacturing site in Malaysia. In order to better serve its customers and respond to future growth of the sector in Southeast Asia, the company is transferring its Malaysian manufacturing base from Penang to Port Klang, Selangor State, the capital region of Malaysia. The new site is expected to be fully operational by the end of the second quarter of 2021. “By investing in a world-class facility in Malaysia we are creating a platform for future growth in Southeast Asia. The new site is strategically located, it is close to our key customers and has easy access to neighboring countries. We will also use the relocation as an opportunity to modernize our equipment and increase automation to improve efficiency. Our initial focus will be on manufacturi

Agfa-Gevaert: Agfa intends to reorganize its Offset Solutions activities – Regulated information21.1.2021 07:45:00 CETPress release

Mortsel, Belgium – January 21, 2021 – 7:45 a.m. CET This press release contains inside information. On January 20, 2021, the Board of Directors expressed the intention to organize the Offset Solutions activities into a stand-alone legal entity structure and organization within the Agfa-Gevaert Group. This intended reorganization is part of the strategic transformation program for the Agfa-Gevaert Group, To improve profitability and to address the significant decline in market demand, Agfa is reviewing its offset business model, simplifying its organization and streamlining its product offering. About Agfa The Agfa-Gevaert Group is a leading company in imaging technology and IT solutions with over 150 years of experience. The Group holds four divisions: Radiology Solutions, HealthCare IT, Digital Print & Chemicals and Offset Solutions. They develop, manufacture and market analogue and digital systems for the healthcare sector, for specific industrial applications and for the printing in

Prosafe SE: Q4 2020 results and webcast on 4 February 202121.1.2021 07:00:00 CETPress release

Prosafe SE will release its fourth quarter 2020 results on 4 February 2021 at approx. 07:00 a.m. CET. The Q4 2020 report and the Q4 2020 presentation will be published on www.newsweb.no and on Prosafe’s website www.prosafe.com Jesper Kragh Andresen, CEO and Stig H. Christiansen, Deputy CEO & CFO will the same day at 10:00 a.m. CET host an audio webcast. The audio webcast can be followed at www.prosafe.com It will be possible to submit questions during the presentation by using the Q&A tool embedded in the audio webcast. These questions will be answered after the presentation. A replay of the audio webcast will be made available at www.prosafe.com shortly after. Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to www.prosafe.com Stavanger, 21 January 2021 Prosafe SE For further information, please contact: Jesper K. Andresen, CEO Phone: +47 51 65 24